AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Apr 27, 2017
35334_dirs_2017-04-27_00abe236-42f9-45f7-9c38-97ac5553ddc4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-04-27
Reporting Person: Equels Thomas K. (Director, CEO, President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-04-27 | Common Stock | P | 72464 | $0.69 | Acquired | 492919 | Direct |